Cover Image

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain

Johanna Lister,1 Sanja Stanisic,1 Klaus Kaier,2 Christian Hagist,2 Dmitry Gultyaev,1 Stefan Walzer31Analytica LA-SER International Inc, Lörrach, Germany; 2Research Centre for Generational Contracts, University of Freiburg, Freiburg, Germany; 3F Hoffmann-La Roche Ltd, Pharmaceuticals Divisio...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lister J (Author), Stanisic S (Author), Kaier K (Author), Hagist C (Author), Gultyaev D (Author), Walzer S (Author)
Format:	Book
Published:	Dove Medical Press, 2012-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
by: Chien C-R, et al.
Published: (2012)

Bevacizumab for glioblastoma
by: Narita Y
Published: (2015)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
by: Benjamin K. Schneider, et al.
Published: (2019)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
by: Fenge Jiang, et al.
Published: (2022)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
by: Di Cao, et al.
Published: (2023)

Bevacizumab-Induced Geographic Tongue
by: Marta Martinez-Garcia, et al.
Published: (2021)

Monitoring antiangiogenesis of bevacizumab in zebrafish
by: Zhang J, et al.
Published: (2018)

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
by: Jing Wang, et al.
Published: (2023)

Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab
by: Suemin Park, et al.
Published: (2024)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022)

Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer
by: Thérèse H Franco, et al.
Published: (2008)

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
by: Frontiers Production Office
Published: (2022)

The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions
by: David Campbell, et al.
Published: (2018)

The combination of MnO2@Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer
by: Jisong Zhang, et al.
Published: (2022)

Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom
by: DiBonaventura MD, et al.
Published: (2013)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)

Pustular psoriasis triggered by therapy with atezolizumab and bevacizumab
by: Mariani Magnus da Luz Andrade, et al.
Published: (2024)

Critical appraisal of bevacizumab in the treatment of ovarian cancer
by: Yoshida H, et al.
Published: (2015)

Direct antitumor activity of bevacizumab: an overlooked mechanism?
by: Zhiyong Wang, et al.
Published: (2024)

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
by: Takahiro Niimura, et al.
Published: (2023)

Campylobacteremia in stage IV gliosarcoma with bevacizumab treatment
by: Ping Liu
Published: (2012)

Downstaging with atezolizumab-bevacizumab: a case series
by: Anand V. Kulkarni, et al.
Published: (2024)

Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials
by: Chen J, et al.
Published: (2015)

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
by: Yusuke Funakoshi, et al.
Published: (2020)

Weichang'an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer-Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1
by: Chuan-Fang Pan, et al.
Published: (2020)

Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer
by: Michiko Nonaka, et al.
Published: (2018)

Prolonged response with bevacizumab in a patient with benign metastasizing leiomyomatosis
by: Shalini Chhabra, et al.
Published: (2022)

Clinical case use bevacizumab for patient with metastatic ovarian cancer
by: M. R. Oganyan, et al.
Published: (2014)

Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases
by: Sávio Lima Sodré, et al.
Published: (2019)

Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies
by: Shu-Ping Lee, et al.
Published: (2019)

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab
by: Naveed Wagle, et al.
Published: (2010)

Bevacizumab Diminishes Inflammation in an Acute Endotoxin-Induced Uveitis Model
by: Salvador Mérida, et al.
Published: (2018)

Antitumor Effect of Bevacizumab in a Xenograft Model of Canine Hemangiopericytoma
by: Masaki Michishita, et al.
Published: (2013)

Comparison of Single-Treatment Efficacy of Bevacizumab and Ranibizumab for Retinopathy of Prematurity
by: Fumio Takano, et al.
Published: (2024)

Eculizumab for bevacizumab induced thrombotic microangiopathy: A case report
by: Mihriban İnözü, et al.
Published: (2022)

A New Bevacizumab Carrier for Intravitreal Administration: Focus on Stability
by: Daniela Chirio, et al.
Published: (2021)

Effect of Osimertinib in Combination With Chemotherapy and Bevacizumab for Untreated Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer: Case Report
by: Haifeng Qin, et al.
Published: (2021)

Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies
by: Xiao Han, et al.
Published: (2023)

Intravitreal Bevacizumab Injection Effect in Exudative Age Related Macular Degeneration
by: Gholamhossein Yaghoobi, et al.
Published: (2016)

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
by: McClung EC, et al.
Published: (2016)